PZRX - PhaseRx, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

PhaseRx, Inc.

410 West Harrison Street
Suite 300
Seattle, WA 98119
United States

Full Time Employees10

Key Executives

Dr. Robert W. Overell Ph.D.Co-Founder, CEO, Pres, Principal Accounting Officer, Sec. & Director487.17kN/A62
Dr. Paul H. Johnson Ph.D.Co-Founder & Director33.12kN/A75
Prof. Allan S. Hoffman Ph.D.Co-FounderN/AN/AN/A
Dr. Patrick S. Stayton Ph.D.Co-FounderN/AN/AN/A
Dr. Oliver W. Press M.D., Ph.D.Co-FounderN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington. On December 11, 2017, PhaseRx, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

PhaseRx, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.